Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 180

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 180
---
 and equipment, net
         
        $
        48,616

        $
        68,227

       Depreciation expense was $17.6 million, $20.5 million and $19.2 million for the year ended December 31, 2024, 2023 and 2022, respectively. See Note 15, Restructurings and Note 10, Leases for more information regarding the impairment losses recognized during the year ended December 31, 2024 and 2023, respectively. 

8.Goodwill and Intangible AssetsThere have been no changes in the carrying amount of goodwill since its recognition in 2015. In conjunction with our organizational realignment in 2024, we allocated goodwill among our two reporting units using a relative fair value approach. Goodwill allocated to the MRD and Immune Medicine reporting units as of December 31, 2024 was $96.4 million and $22.6 million, respectively.Intangible assets subject to amortization as of December 31, 2024 and 2023 consisted of the following (in thousands):  

        December 31, 2024

        Gross Carrying Amount

        Accumulated Amortization

        Net Carrying Amount

        Acquired developed technology
         
        $
        20,000

        $
        (16,641
        )
         
        $
        3,359

        Purchased intellectual property

        325

        (259
        )

        66

        Balance at December 31, 2024
         
        $
        20,325

        $
        (16,900
        )
         
        $
        3,425

        December 31, 2023

        Gross Carrying Amount

        Accumulated Amortization

        Net Carrying Amount

        Acquired developed technology
         
        $
        20,000

        $
        (14,970
        )
         
        $
        5,030

        Purchased intellectual property

        325

        (227
        )

        98

        Balance at December 31, 2023
         
        $
        20,325

        $
        (15,197
        )
         
        $
        5,128

       The developed technology was acquired in connection with our acquisition of Sequenta, Inc. in 2015. The remaining balance of the acquired developed